Recent advances in the management of Hodgkin lymphoma

4Citations
Citations of this article
32Readers
Mendeley users who have this article in their library.

Abstract

Hodgkin lymphoma (HL) is a rare cancer of the immune system that typically affects lymph nodes and sometimes other organs. Although the majority of patients can be potentially cured with the use of multi-agent chemotherapy and radiotherapy, a proportion of them will relapse or develop resistant disease for which treatment options are limited. In recent years, new agents have been developed and tested in HL with encouraging results. Two classes of drugs stand out as highly active in advanced HL based on recent study results: antibody-drug conjugates and programmed death 1 inhibitors. Clinical trials in HL with these agents have been completed in the past several years and the results have recently become available. In this review, we discuss the recent advances in the management of HL with a focus on strategies to decrease toxicity and a review of the two drug classes that have the potential to change the landscape of treatment of this disease.

Cite

CITATION STYLE

APA

Villasboas, J. C., & Ansell, S. M. (2016). Recent advances in the management of Hodgkin lymphoma. F1000Research. Faculty of 1000 Ltd. https://doi.org/10.12688/f1000research.8301.1

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free